Clinical Trial Update: AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 trial of AC6 gene transfer in patients with reduced left ventricular ejection fraction heart failure has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• AC6 gene transfer

Snippet

Sponsor: Renova Therapeutics | Conditions: Heart Failure | Phase 3 | Status: WITHDRAWN